Swiss Parenterals Limited — Taila Exporter Profile
Indian Pharmaceutical Exporter · #3 for Taila · $464.2K export value · DGFT Verified
Swiss Parenterals Limited is the #3 Indian exporter of Taila with $464.2K in export value and 15 verified shipments. Swiss Parenterals Limited holds a 6.1% market share in Taila exports across 6 countries. The company exports 18 pharmaceutical products worth $15.9M across 9 therapeutic categories.
Swiss Parenterals Limited — Taila Export Profile: Buyers & Destinations
Where Does Swiss Parenterals Limited Export Taila?
| Country | Value | Shipments | Share |
|---|---|---|---|
| VIETNAM DEMOCRATIC REP. OF | $110.0K | 3 | 24.6% |
| VIETNAM, DEMOCRATIC REP. OF | $97.8K | 3 | 21.9% |
| LIBYA | $66.1K | 3 | 14.8% |
| UGANDA | $57.5K | 3 | 12.9% |
| SWITZERLAND | $50.0K | 1 | 11.2% |
| THAILAND | $50.0K | 1 | 11.2% |
| BENIN | $15.3K | 1 | 3.4% |
Swiss Parenterals Limited exports Taila to 7 countries. The largest destination is VIETNAM DEMOCRATIC REP. OF accounting for 24.6% of Swiss Parenterals Limited's Taila shipments, followed by VIETNAM, DEMOCRATIC REP. OF (21.9%) and LIBYA (14.8%). These destinations reflect Swiss Parenterals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Taila from Swiss Parenterals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| HATAY PHARMACEUTICAL JOINT STOCK CO | VIETNAM, DEMOCRATIC REP. OF | $207.8K | 6 |
| FIRST GULF LIBYAN BANK | LIBYA | $66.1K | 3 |
| SHREEJI PHARMACEUTICALS LTD. | UGANDA | $57.5K | 3 |
| TO THE ORDER OF | SWITZERLAND | $50.0K | 1 |
| CITIBANK N.A. BANGKOK | THAILAND | $50.0K | 1 |
| SOBAPS S A | BENIN | $15.3K | 1 |
Swiss Parenterals Limited supplies Taila to 6 buyers globally. The largest buyer is HATAY PHARMACEUTICAL JOINT STOCK CO (VIETNAM, DEMOCRATIC REP. OF), followed by FIRST GULF LIBYAN BANK (LIBYA) and SHREEJI PHARMACEUTICALS LTD. (UGANDA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Taila Export Value and How Much Does Swiss Parenterals Limited Contribute?
India exported $6.4M worth of Taila through 6,969 shipments from 208 suppliers to 82 countries, serving 381 buyers globally. Swiss Parenterals Limited contributes $464.2K to this total, accounting for 6.1% of India's Taila exports. Swiss Parenterals Limited ships Taila to 7 countries through 6 buyers.
What Is the Average Shipment Value for Swiss Parenterals Limited's Taila Exports?
Swiss Parenterals Limited's average Taila shipment value is $30.9K per consignment, based on 15 shipments totaling $464.2K. The largest destination is VIETNAM DEMOCRATIC REP. OF (24.6% of Swiss Parenterals Limited's Taila exports).
How Does Swiss Parenterals Limited Compare to Other Indian Taila Exporters?
Swiss Parenterals Limited ranks #3 among 208 Indian Taila exporters with a 6.1% market share. The top 3 exporters are GREENSHIP EXPORTS ($3.8M), SNA OUSHADHASALA PRIVATE LIMITED ($791.9K), SWISS PARENTERALS LIMITED ($464.2K). Swiss Parenterals Limited processed 15 shipments to 6 destination countries.
What Taila Formulations Does Swiss Parenterals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - PDSOLONE-125 MG (DETAILAS PER INVOICE) (100000 BOXES)NOS | $110.0K | 3 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - PDSOLONE-125 MG (DETAILAS PER INVOICE) (90000 BOXES)NOS | $97.8K | 3 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - SWISSCLOXA INJ. (DETAILAS PER INVOICE) (500000 VIALS)NOS | $57.5K | 3 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - SULBACEF 1.5 GM (DETAILAS PER INVOICE) (49300 PACKS) | $50.0K | 1 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - NORENE INJ 4 ML (DETAILAS PER INVOICE) (10350 BOXES)NOS | $50.0K | 1 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE:SWISSCILLIN 500 MG DETAILAS PER DOCUMENT | $40.6K | 2 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE:SWISSCILLIN 1 GM DETAILAS PER DOCUMENT | $25.5K | 1 |
| PHARMACEUTICAL GOODS HARMLESS MEDICINESFOR HUMAN USE DICLOFENAC SODIUM DETAILAS PER INVOICE 300000 AMPS | $15.3K | 1 |
Swiss Parenterals Limited exports 8 distinct Taila formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - PDSOL with 3 shipments worth $110.0K.
How Does Swiss Parenterals Limited Compare to Nearest Taila Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | GREENSHIP EXPORTS | $3.8M | 1,742 | 8 | $2.2K |
| 2 | SNA OUSHADHASALA PRIVATE LIMITED | $791.9K | 147 | 8 | $5.4K |
| 3 | SWISS PARENTERALS LIMITED ★ | $464.2K | 15 | 6 | $30.9K |
| 4 | SREE EXPORTS | $314.8K | 662 | 2 | $475 |
| 5 | KOOTHADEES TRADE PRIVATE LIMITED | $255.7K | 322 | 1 | $794 |
Swiss Parenterals Limited ranks #3 among 208 Indian Taila exporters. Average shipment value of $30.9K compared to the market average of $30.9K. The closest competitors by value are GREENSHIP EXPORTS and SNA OUSHADHASALA PRIVATE LIMITED.
Which Indian Ports Ship Taila Exports?
| Port | Shipments | % Share |
|---|---|---|
| COCHIN SEA (INCOK1) | 1,341 | 19.2% |
| COCHIN SEA | 1,181 | 16.9% |
| TUTICORIN SEA | 533 | 7.6% |
| TUTICORIN SEA (INTUT1) | 529 | 7.6% |
| Cochin Sea | 349 | 5.0% |
| CHENNAI SEA (INMAA1) | 295 | 4.2% |
| DELHI AIR CARGO ACC (INDEL4) | 293 | 4.2% |
| Tuticorin Sea | 250 | 3.6% |
Geopolitical & Trade Policy Impact on Swiss Parenterals Limited's Taila Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Swiss Parenterals. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight costs and extended delivery times. Such maritime challenges can significantly impact the timely distribution of pharmaceuticals, especially to Middle Eastern markets. (pharmaceuticalcommerce.com)
Conversely, escalating US-China trade tensions have prompted the United States to diversify its import sources, potentially benefiting Indian exporters. However, recent US tariff policies, including a 25% tariff on Indian imports due to geopolitical alignments, pose a substantial challenge, potentially affecting nearly 55% of India's exports to the US. (apnews.com)
In the European Union, stringent regulatory frameworks like the Falsified Medicines Directive necessitate compliance with rigorous safety and quality standards. For companies like Swiss Parenterals, adhering to these regulations is crucial to maintain and expand their presence in EU markets.
Swiss Parenterals Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened scrutiny regarding quality and compliance. Indian exporters, including Swiss Parenterals, must navigate complex regulatory environments, ensuring adherence to FDA, WHO, and EU GMP standards. The US FDA's increased inspections of Indian facilities underscore the importance of maintaining high-quality manufacturing practices to avoid potential export bans or recalls. (fact.net.in)
Swiss Parenterals' integration into Eris Lifesciences is expected to bolster its compliance infrastructure, leveraging Eris's established quality management systems to meet international regulatory requirements effectively.
About Swiss Parenterals Limited
Swiss Parenterals Limited exports 18 products worth $15.9M. Beyond Taila, top products include Ceftriaxone, Meropenem, Prednisolone, Fosfomycin, Methylprednisolone. View the complete Swiss Parenterals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Taila — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Taila shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Swiss Parenterals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 15 individual customs records matching Swiss Parenterals Limited exporting Taila, covering 8 formulations to 7 countries via 6 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 82+ countries, 381+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Taila Export Data from Swiss Parenterals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Swiss Parenterals Limited's Taila exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Swiss Parenterals Limited
Full Company Profile →
18 products · $15.9M total trade · 9 categories
Taila Stats
Company Overview
Top Products by Swiss Parenterals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Swiss Parenterals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Taila. For current shipment-level data, contact TransData Nexus.